Intravitreal Aflibercept Injection in Vision Impairment Due to DME

Phase 3

Completed

• Conditions: Macular Edema; Diabetes Mellitus
• Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Macular Laser Photocoagulation (Control)

• Registration Number: NCT01331681
• Lead Sponsor: Bayer

Brief Summary

To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-04-07
• Study First Submitted QC: 2011-04-07
• Study First Posted: 2011-04-08
• Study Start: 2011-05-09
• Primary Completion: 2013-06-03
• Disposition First Submitted: 2014-03-31
• Disposition First Submitted QC: 2014-04-30
• Disposition First Posted: 2014-05-14
• Results First Submitted: 2014-08-29
• Results First Submitted QC: 2014-08-29
• Results First Posted: 2014-09-09
• Study Completion: 2015-03-30
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-05
• Last Update Posted: 2023-11-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 406

Inclusion Criteria

• Adults ≥ 18 years with type 1 or 2 diabetes mellitus
• Subjects with DME secondary to diabetes mellitus involving the center of the macula in the study eye
• Decrease in vision determined to be primarily the result of DME in the study eye
• BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye

Read More

Exclusion Criteria

• Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1
• More than 2 previous macular laser treatments in the study eye
• Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of Day 1
• Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1
• Active proliferative diabetic retinopathy (PDR) in the study eye, with the exception of inactive, regressed PDR
• Uncontrolled diabetes mellitus, as defined by HbA1c > 12%
• Only 1 functional eye even if that eye is otherwise eligible for the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intravitreal Aflibercept Injection 2Q4	VEGF Trap-Eye (BAY86-5321)	Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Intravitreal Aflibercept Injection 2Q8	VEGF Trap-Eye (BAY86-5321)	Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
Macular Laser Photocoagulation (Control)	Macular Laser Photocoagulation (Control)	Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)	Baseline up to Week 52	Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF	Baseline up to Week 52	Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF	Baseline up to Week 52	Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF	Baseline up to Week 52	Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF	Baseline up to Week 52
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF	Baseline up to Week 52	The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF	Baseline up to Week 52	The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.

Trial Locations

Locations (4)

Klinikum der Stadt Ludwigshafen am Rhein gGmbH; 🇩🇪 Ludwigshafen, Rheinland-Pfalz, Germany

IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico; 🇮🇹 Milano, Italy

Hopital Lariboisiere; 🇫🇷 Paris, France

Faculty Hospital Hradec Kralove; 🇨🇿 Hradec Kralove, Czechia